|
References
1. Martin, D.R., Semelka, R.C. (2006). Health effects of ionising radiation from diagnostic CT. Lancet, 367, 1712-4.
2. Bettmann, M.A., Heeren, T., Greenfield, A., & Goudey, C. (1997). Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry. Radiology, 203, 611-20.
3. Bettmann, M. A. MD. (2004). Frequently asked questions: iodinated contrast agents. RadioGraphics, 24, S3-S1.
4. American College of Radiology. American College of Radiology manual on contrast media, 4th Edition. Reston, Va: American College of Radiology, 1998.
5. American College of Radiology Committee on Drugs and Contrast Media. Manual on contrast media. 5th Edition. Reston, Va: American College of Radiology, 2004.
6. Lasser, E.C., Berry, C.C., Talner, L.B., et al. (1987). Pre-treatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med, 317, 845-49.
7. Greenberger, P.A., & Patterson, R. (1991). The prevention of immediate generalized reactions to radiocontrast media in high risk patients. J Allergy Clin Immunol, 87, 867-72.
8. Lasser, E.C., Berry, C.C., Mishkin. M.M., Williamson, B., Zheutlin, N., & Silverman, J.M. (1994). Pretreatment with corticosteroids to prevent adverse reactions to nonionic contrast media. Am J Roentgenol, 162, 523-26.
9. Katayama, H., Yamaguchi, K., Kozuka, T., Takashima, T., Seez, P., & Matsuura, K. (1990). Adverse reactions to ionic and nonionic contrast media: a report from the Japanese Committee on the Safety of Contrast Media. Radiology, 175, 621-28.
10. Rudnick, M.R., Goldfarb, S., Wexler, L., et al. (1995). Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int, 47, 254-61.
11. Katholi, R.E., Taylor, G.J., Woods, W.T., Womack, K.A., Katholi, C.R., McCann, W.P., Moses, H.W., Dove, J.T., Mikell, F.L., Woodruff, R.C., Miller, B.D., & Schneider, J.A. (1993). Nephrotoxicity of nonionic low-osmolality versus ionic high-osmolality contrast media: a prospective double-blind randomized comparison in human beings. Radiology, 186, 183-87.
12. Bailey, C.J., & Turner, R.C. (1996). Metformin. N Engl J Med, 334, 574-9.
13. Cockcroft, D.W., & Gault, M.H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41.
14. Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N., & Roth, T. (1999). A more accurate method to estimate glomerular infiltration rate from serum creatinine: a new prediction equation. Ann Intern Med, 130, 461-70.
15. Shusterman, N., Strom, B.L., Murray, T.G., Morrison, G., West, S.L., & Maislin, G. (1987). Risk factors and outcome of hospital-acquired acute renal failure: clinical epidemiologic study. Am J Med, 83, 65-71.
16. Levy, E.M., Viscoli, C.M., & Horwitz, R.I. (1996). The effect of acute renal failure on mortality: a cohort analysis. JAMA, 275, 1489-94.
17. Parfrey, P.S., Griffiths, S.M., Barrett, B.J., et al. (1989). Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency or both: a prospective controlled study. N Engl J Med, 320, 143-49.
18. Cigarroa, R.G., Lange, R.A., Williams, R.H., & Hillis, L.D. (1989). Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med, 86, 649-52.
19. McCullough, P., Wolyn, R., Rocher, L., Levin, R., & O'Neill, W. (1997). Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med, 103, 368-75.
20. Solomon, R., Werner, C., Mann, D., D'Elia, J., & Silva, P. (1994). Effects of saline, mannitol and furosemide on acute decreases in renal function induced by contrast agents. N Engl J Med, 331, 1416-20.
21. Trivedi, H.S., Moore, H., Nasr, S., et al. (2003). A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract, 93, C29-34.
22. Mueller, C., Buerkle, G., Buettner, H.J., et al. (2002). Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med, 162, 329-36.
23. Merten, G.J., Burgess, W.P., Gray, L.V., et al. (2004). Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA, 291, 2328-34.
24. Tepel, M., van der Giet, M., Schwartzfeld, C., Laufer, U., Liermann, D., & Zidek, W. (2000). Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med, 343, 180-4.
25. Pannu, N., Manns, B., Lee, H., & Tonelli, M. (2004). Systematic review of the impact of n-acetylcysteine on contrast nephropathy. Kidney Int, 65, 1366-74.
26. Kshirsagar, A.V., Poole, C., Mottl, A., et al. (2004). N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol, 15, 761-69.
27. Kay, J., Chow, W.H., Chan, T.M., et al. (2003). Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA, 289, 553-58.
28. Chalmers, N., & Jackson, R.W. (1999). Comparison of iodixanol and iohexol in renal impairment. Br J Radiol, 72, 701-03.
29. Apelin, P., Aubry, P., Fransson, S.G., et al. (2003). Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med, 348, 491-99.
30. Yoshikawa, H. (1992). Late adverse reactions to nonioniccontrast media. Radiology, 183, 737-40.
31. Sadowski, E.A., Bennett, L.K., Chan, M.R., Wentland, A.L., Garrett, A.L., Garrett, R.W., & Djamali, A. (2007). Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology, 243, 148-57.
32. Grobner, T. (2006). Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant, 21(4), 1104-08.
33. Mendoza, F.A., Artlett, C.M., Sandorfi, N., Latinis, K., Piera-Velazquez, S., & Jimenez, S.A. (2006). Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum, 35(4), 238-49.
34. Swaminathan, S., & Leung, N. (2006). Nephrogenic fibrosing dermopathy: lessons from the past. Int J Dermatol, 45(6), 639-41.
35. Marckmann, P., Skov, L., Rossen, K., et al. (2006). Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol, 17(9), 2359-62.
36. Thomsen, H.S., Morcos, S.K., & Dawson, P. (2006). Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol, 905-06.
37. High, W.A., Ayers, R.A., Chandler, J., Zito, G., & Cowper, S.E. (2007). Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol, 56, 21-26.
38. Boyd, A.S., Zic, J.A., & Abraham, J.L. (2007). Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol, 56, 27-30.
39. Public health advisory: gadolinium-containing contrast agents for magnetic resonance imaging (MRI)-Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. U.S. Food and Drug Administration. www.fda.gov/cder/drug/advisory/gadolinium_agents.htm. Published June 8, 2006. Updated Dec. 22, 2006. Accessed Dec. 7, 2006.
40. High, W.A., Ayers, R.A., & Cowper, S.E. (2007). Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol, 56, 710-12.
|